In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

After GSK late last year celebrated a head-to-head win for its cancer drug Jemperli against Merck & Co.’s Keytruda, the companies are offering another opportunity to compare their PD-1 inhibitors side by side. Only this time, the GSK latecomer appears to have lost its competitive edge, according to a cross-trial review of the latest results.